Recent News

572 News Items found
Hyperpolarized MRI
In the Clinic
Hyperpolarized MRI could allow doctors to get a read on a tumor’s response to treatment quickly.
Test tubes and glass vials and beakers sit on a desk in a laboratory.
In the Lab
A new Sloan Kettering Institute program will enhance the use of chemical principles to investigate biological processes.
Organoid cell structures fluorescing in blue, green, and purple.
In the Lab
For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.
Proximal tubule of the kidney.
In the Lab
Memorial Sloan Kettering scientists have engineered a tiny particle that could ferry drugs directly to the kidneys and prevent their uptake in other organs.
MSK investigators Joan Massagué and Anna Obenauf
In the Lab
Outsmarting Cancer’s Survival Skills
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
CAR T cell therapy
In the Clinic
Cell therapies that use patients’ own immune cells to attack cancer — including CAR T cell therapy, an approach developed at MSK — are a promising and rapidly growing area of research.
Epigenetics
Q&A
An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.
Neurons created from embryonic stem cells
In the Lab
A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.
Pictured: Viviane Tabar
In the Lab
Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.
MSK investigators Michael Berger and David Solit.
Finding
A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.